About Actinium PharmaceuticalsActinium Pharmaceuticals, Inc.
NEW YORK--(BUSINESS WIRE)--
Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB) ("Actinium" or "the
Company"), a biopharmaceutical Company developing innovative targeted
payload immunotherapeutics for the treatment of advanced cancers,
announced today that Dr. Kaushik J. Dave, President and CEO, will
present at the Biotech Showcase™ 2014 conference from January 13th
to 15th, 2014. Dr. Dave will present a corporate update on
Monday, January 13, 2014 at 4:30 pm Pacific.
is a New York
-based biopharmaceutical company developing innovative
targeted payload immunotherapeutics for the treatment of advanced
cancers. Actinium's targeted radiotherapy is based on its proprietary
delivery platform for the therapeutic utilization of alpha-emitting
actinium-225 and bismuth-213 and certain beta emitting
radiopharmaceuticals in conjunction with monoclonal antibodies. The
Company’s lead radiopharmaceutical Iomab™-B will be used in preparing
patients for hematopoietic stem cell transplant, commonly referred to as
bone marrow transplant. The Company is conducting a single, pivotal,
multicenter Phase 3 clinical study of Iomab™-B in refractory and
relapsed Acute Myeloid Leukemia (AML) patients over the age of 55 with a
primary endpoint of durable complete remission. The company’s second
program, Actimab-A, is continuing its clinical development in a Phase
1/2 trial for newly diagnosed AML patients over the age of 60 in a
single-arm multicenter trial. For more information, please visit www.actiniumpharmaceuticals.com
For more information:
Visit our web site www.actiniumpharmaceuticals.comForward-Looking Statement for Actinium Pharmaceuticals, Inc.
This news release contains “forward-looking statements” as that term is
defined in the Private Securities Litigation Reform Act of 1995. These
statements are based on management's current expectations and involve
risks and uncertainties, which may cause results to differ materially
from those set forth in the statements. The forward-looking statements
may include statements regarding product development, product potential,
or financial performance. No forward-looking statement can be guaranteed
and actual results may differ materially from those projected. Actinium
undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events, or otherwise.
Actinium Pharmaceuticals, Inc.
Source: Actinium Pharmaceuticals, Inc.